Cargando…

Hypercalcemia as a Rebound Phenomenon of LOXO-292 Efficacy in Medullary Thyroid Cancer

Detalles Bibliográficos
Autores principales:	Kian, Waleed, Levitas, Dina, Alguayn, Wafeek, Shalata, Walid, Sharb, Adam A., Levin, Daniel, Roisman, Laila C., Tokar, Margarita, Peled, Nir, Yakobson, Alexander
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2020
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8474458/ https://www.ncbi.nlm.nih.gov/pubmed/34589909 http://dx.doi.org/10.1016/j.jtocrr.2020.100002

Ejemplares similares

Safety of the BNT162b2 mRNA COVID-19 vaccine in oncologic patients undergoing numerous cancer treatment options: A retrospective single-center study
por: Kian, Waleed, et al.
Publicado: (2022)

Epithelioid Hemangioendothelioma and Epithelioid Hemangioma: Pazopanib as a Potential Salvage Therapy
por: Yakobson, Alexander, et al.
Publicado: (2021)

Overcoming CEP85L-ROS1, MKRN1-BRAF and MET amplification as rare, acquired resistance mutations to Osimertinib
por: Kian, Waleed, et al.
Publicado: (2023)

1589P Safety of the BNT162b2 mRNA COVID-19 vaccine in oncologic patients undergoing numerous cancer treatment options
por: Zemel, M., et al.
Publicado: (2021)

Programmed death-ligand 1 expression discrepancy between primary tumor and metastatic lymph nodes in non-small cell lung cancer
por: Kian, Waleed, et al.
Publicado: (2020)

Systemic and CNS Activity of Selective RET Inhibition With Selpercatinib (LOXO-292) in a Patient With RET-Mutant Medullary Thyroid Cancer With Extensive CNS Metastases
por: Andreev-Drakhlin, Alexander, et al.
Publicado: (2020)

SUN-LB75 The Anti-Tumor Activity of the Selective Ret Inhibitor Selpercatinib (LOXO-292) in Medullary Thyroid Cancer Is Independent of the Specific RET Mutation
por: Cabanillas, Maria E, et al.
Publicado: (2020)

Real-world efficacy and safety of mobocertinib in EGFR exon 20 insertion-mutated lung cancer
por: Kian, Waleed, et al.
Publicado: (2022)

Intravenous immunoglobulin efficacy on pembrolizumab induced severe toxic epidermal necrolysis
por: Kian, Waleed, et al.
Publicado: (2021)

Associated Myocarditis: A Predictive Factor for Response?
por: Shalata, Walid, et al.
Publicado: (2020)

Activity of the Highly Specific RET Inhibitor Selpercatinib (LOXO-292) in Pediatric Patients With Tumors Harboring RET Gene Alterations
por: Ortiz, Michael V., et al.
Publicado: (2020)

Response to Selective RET Inhibition With LOXO-292 in a Patient With RET Fusion-Positive Lung Cancer With Leptomeningeal Metastases
por: Guo, Robin, et al.
Publicado: (2019)

Complete Response to Selective RET Inhibition With Selpercatinib (LOXO-292) in a Patient With RET Fusion–Positive Breast Cancer
por: Watanabe, Satomi, et al.
Publicado: (2021)

Rapid Response to the Combination of Lenvatinib and Pembrolizumab in Patients with Advanced Carcinomas (Lung Adenocarcinoma and Malignant Pleural Mesothelioma)
por: Shalata, Walid, et al.
Publicado: (2021)

NKp44-Derived Peptide Used in Combination Stimulates Antineoplastic Efficacy of Targeted Therapeutic Drugs
por: Iraqi, Muhammed, et al.
Publicado: (2022)

Rebound Hypercalcemia After Denosumab Therapy in a Child With Cherubism
por: Litao, Melissa Kaori S, et al.
Publicado: (2021)

Denosumab-Induced Rebound Hypercalcemia Treated With Bisphosphonates in a Pediatric Patient
por: Gandolfi, Anne, et al.
Publicado: (2023)

Denosumab Discontinuation and the Rebound Phenomenon: A Narrative Review
por: Anastasilakis, Athanasios D., et al.
Publicado: (2021)

Osteoclast Recycling and the Rebound Phenomenon Following Denosumab Discontinuation
por: Kim, Albert S., et al.
Publicado: (2022)

Beta-blocker Rebound Phenomenon in an Adolescent with Graves’ Disease
por: Anık, Ahmet
Publicado: (2022)

Symptomatic Rebound Hypercalcemia After Denosumab Discontinuation in a Pediatric Patient With Cherubism
por: Marpuri, Ian, et al.
Publicado: (2021)

Neoadjuvant and Adjuvant Immunotherapy in Early-Stage Non-Small-Cell Lung Cancer, Past, Present, and Future
por: Szeto, Chun Ho, et al.
Publicado: (2021)

Dose escalation of osimertinib for intracranial progression in EGFR mutated non-small-cell lung cancer with brain metastases
por: Goldstein, Iris M, et al.
Publicado: (2020)

Metabolic Activity Assessment by 18F-Fluorodeoxyglucose Positron Emission Tomography in Patients after COVID-19 Vaccination
por: Shalata, Walid, et al.
Publicado: (2022)

A Postoperative Phenomenon of Percutaneous Endoscopic Lumbar Discectomy: Rebound Pain
por: Zhang, Chang, et al.
Publicado: (2021)

Kaposiform hemangioendothelioma with fatal income: Kasabach–Merritt phenomenon and hypercalcemia
por: Massara, Baklouti, et al.
Publicado: (2022)

Head rebound test in the clinical neurological examination of veterinary patients: a case example and discussion of Stewart and Holmes’ rebound phenomenon
por: Santifort, Koen M.
Publicado: (2023)

Radiological artificial intelligence - predicting personalized immunotherapy outcomes in lung cancer
por: Roisman, Laila C., et al.
Publicado: (2023)

COVID-19 Pandemic and Possible Rebound Phenomenon in Incidence of Acute Myocardial Infarction
por: Čulić, Viktor, et al.
Publicado: (2021)

Clinical features of COVID-19 patients with rebound phenomenon after corticosteroid therapy
por: Murakami, Koji, et al.
Publicado: (2022)

Lung Cancer in Young Patients: Higher Rate of Driver Mutations and Brain Involvement, but Better Survival
por: Suidan, Anna May, et al.
Publicado: (2019)

PD-1 Inhibitors in Elderly and Immunocompromised Patients with Advanced or Metastatic Cutaneous Squamous Cell Carcinoma
por: Yakobson, Alexander, et al.
Publicado: (2023)

To rebound or not to rebound
por: Stahl, Bethany A, et al.
Publicado: (2017)

Infantile Fibrosarcoma With NTRK3–ETV6 Fusion Successfully Treated With the Tropomyosin‐Related Kinase Inhibitor LOXO‐101
por: Nagasubramanian, Ramamoorthy, et al.
Publicado: (2016)

Poster Sessions 292 - 465
Publicado: (2003)

Tolerated Re-Challenge of Immunotherapy in a Patient with ICI Associated Myocarditis: A Case Report and Literature Review
por: Shalata, Walid, et al.
Publicado: (2023)

Bullous Pemphigoid Occurring after Stopping Imatinib Therapy of CML: Is a Continuation of Post-Treatment Follow-Up Needed?
por: Yakobson, Alexander, et al.
Publicado: (2023)

Cemiplimab as First Line Therapy in Advanced Penile Squamous Cell Carcinoma: A Real-World Experience
por: Rouvinov, Keren, et al.
Publicado: (2023)

Foramen of Winslow hernia years after a Ladd’s procedure: A case report
por: Abu-Swis, Shadi, et al.
Publicado: (2020)

Cardiac Toxicity Associated with Immune Checkpoint Inhibitors: A Systematic Review
por: Shalata, Walid, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_643var4028sjbbsk73brqprds5